Hyperhomocysteinaemia is a significant risk factor for white matter lesions in Japanese type 2 diabetic patients

Orlistat induces weight loss by blocking hydrolysis of triglyceride in the intestine, and has thereby been associated with favorable changes in postprandial triglycerides (ppTGL). Some epidemiological studies have identified ppTGL concentrations as a significant risk factor for cardiovascular disease. Oral fat loading test (OFLT) has been used for screening of elevated levels of ppTGL. The objective of the present systematic review is to present available data on the effects of orlistat on OFLT.We found 11 studies, seven of which studied the effect of a single dose of orlistat on OFLT in three healthy volunteers, one with obesity, two with type-2 diabetes and one with hyperlipidemic patients. The other four studied the effect of orlistat on OFLT, but after a previous period of time with daily treatment with orlistat: 1 healthy volunteer, 2 obese volunteers, and one patient with hyperlipidemia.Our systematic review suggests that orlistat can help to reduce postprandial hypertriglyceridemia in obese, dyslipemic and type-2 diabetic patients. Regarding free fatty acids, they could be reduced but not all the authors have found the same results. In relation to type-2 diabetic patients, we have found three studies with conflicting results on the immediate effect of orlistat on the postprandial GLP-1 response.In conclusion, orlistat can help to reduce postprandial plasmatic TGL, especially in patients with postprandial hypertriglyceridemia related to obesity, dyslipidemia or type-2 diabetes.

Download Full-text

Anti-thyroid antibodies as an additional risk factor for endothelial dysfunction in type 2 diabetic patients with subclinical hypothyroidism

Endocrine Abstracts ◽

10.1530/endoabs.41.ep222 ◽

2016 ◽

Author(s):

Lilit Petrosyan

Keyword(s):

Risk Factor ◽

Endothelial Dysfunction ◽

Subclinical Hypothyroidism ◽

Diabetic Patients ◽

Additional Risk Factor ◽

Thyroid Antibodies ◽

Type 2 Diabetic Patients ◽

Additional Risk ◽

Type 2 Diabetic

Download Full-text

Type-2 Diabetes as a Risk Factor for Severe COVID-19 Infection

Microorganisms ◽

10.3390/microorganisms9061211 ◽

2021 ◽

Vol 9 (6) ◽

pp. 1211

Author(s):

Mahnaz Norouzi ◽

Shaghayegh Norouzi ◽

Alistaire Ruggiero ◽

Mohammad S. Khan ◽

Stephen Myers ◽

...

Keyword(s):

Type 2 Diabetes ◽

Risk Factor ◽

Inflammatory Responses ◽

Significant Risk ◽

Significant Risk Factor ◽

Diabetic Patients ◽

Angiotensin Converting Enzyme 2 ◽

Immune System Dysfunction ◽

Current Outbreak

The current outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), termed coronavirus disease 2019 (COVID-19), has generated a notable challenge for diabetic patients. Overall, people with diabetes have a higher risk of developing different infectious diseases and demonstrate increased mortality. Type 2 diabetes mellitus (T2DM) is a significant risk factor for COVID-19 progression and its severity, poor prognosis, and increased mortality. How diabetes contributes to COVID-19 severity is unclear; however, it may be correlated with the effects of hyperglycemia on systemic inflammatory responses and immune system dysfunction. Using the envelope spike glycoprotein SARS-CoV-2, COVID-19 binds to angiotensin-converting enzyme 2 (ACE2) receptors, a key protein expressed in metabolic organs and tissues such as pancreatic islets. Therefore, it has been suggested that diabetic patients are more susceptible to severe SARS-CoV-2 infections, as glucose metabolism impairments complicate the pathophysiology of COVID-19 disease in these patients. In this review, we provide insight into the COVID-19 disease complications relevant to diabetes and try to focus on the present data and growing concepts surrounding SARS-CoV-2 infections in T2DM patients.

Download Full-text